I am a research chemist who has a PhD in organic chemistry and was a postdoctoral fellow in medicinal chemistry at Memorial Sloan Kettering. My main interest is to develop new drugs and diagnostic agents for cancer. My research focus at Memorial Sloan Kettering has been to design and synthesize tyrosine-kinase targeted therapeutics for leukemia and other malignancies. Additionally, I have a particular interest in developing molecular tools that can improve cancer diagnosis and therapy. These include both optical and radiolabeled probes and molecular conjugates. Also, I am interested in understanding how these molecules behave in vitro and in vivo. We use non-invasive imaging techniques like PET and SPECT to directly observe drug and radiotracer behavior in the body. With the help of like-minded fellow scientists and physicians, I hope to improve many aspects of cancer treatment by developing tools to diagnose cancer earlier and find new drugs that are effective with fewer side effects. Such lofty goals are indeed attainable in this highly collaborative environment at Memorial Sloan Kettering Cancer Center.
As home to one of the world’s top cancer research centers, Memorial Sloan Kettering is typically involved in more than 900 clinical trials at a given time. Currently, clinical trials focused on the conditions I treat are enrolling new patients. If you’re interested in joining a clinical trial, click to learn about the trial’s purpose, eligibility criteria, and how to get more information.Learn more
Most major health insurers offer plans that include MSK as one of their in-network providers. If MSK is in-network, it means all our doctors are too. Medicare and New York State Medicaid also provide benefits for care at MSK.Learn more